Neuronetics, Inc. (NASDAQ: STIM) announced its financial results for the fourth quarter and full year ended December 31, 2025, showcasing significant growth driven by the acquisition of Greenbrook TMS Inc. The company reported total revenue of $41.8 million for Q4 2025, marking an impressive 86% increase compared to the same period in 2024. On an adjusted pro forma basis, revenue grew by 23%. Notably, Greenbrook clinic revenue surged to $23.5 million in Q4 2025, reflecting a staggering 428% increase as reported and a 37% rise on an adjusted basis. The company also highlighted its continued improvement in cash management, with cash provided by operations reaching $0.9 million in Q4 2025.

Looking ahead, Neuronetics expects full-year 2026 revenue to range between $160 million and $166 million. The company has also appointed Daniel L. Reuvers as its new President and Chief Executive Officer, effective March 23, 2026. Reuvers brings over 30 years of experience in the medical device industry, having previously served as CEO of Tactile Medical. His leadership is anticipated to drive Neuronetics' growth strategy further.

The company’s operational highlights include advancements in its collaboration with Compass Pathways on COMP360 psilocybin for treatment-resistant depression, and an expansion of TRICARE West coverage to include adolescents aged 15 and older struggling with depression. These developments underscore Neuronetics' commitment to enhancing access to innovative mental health treatments. The company is entering 2026 with strong momentum and a clear outlook for growth, positioning itself as a leader in the neurohealth therapy market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.